论文部分内容阅读
过去20年,虽已对癌瘤病人的血清核糖核酸酶(SRNase)活性升高引起关注,但它与癌瘤之间的关系,只是在最近由于应用了人工合成的多核苷酸为底物来测定RNase,才有了较为充分的论证。 SRNase活性升高和癌瘤的关系 Fink等报导,以poly C为底物时,93%多发性骨髓瘤病人的SRNase活性明显升高。Reddi报导,胰腺癌病人的SRNase活性比正常人高两倍多;乳腺癌、结肠癌和肺癌等病人,该酶的活性亦多有不同程度的升高;但在胰腺炎病人则正常。
Although interest in serum RNAse (SRNase) activity in cancer patients has increased over the past 20 years, its relationship with cancer is only recently due to the use of artificially synthesized polynucleotides as substrates. The determination of RNase has been fully demonstrated. Relationship between increased SRNase activity and cancerous tumors Fink et al reported that when poly C was used as a substrate, SRNase activity was significantly increased in 93% of multiple myeloma patients. Reddi reported that the SRNase activity of patients with pancreatic cancer was more than twice as high as that of normal people. The activity of this enzyme also increased to varying degrees in patients with breast cancer, colon cancer, and lung cancer, but it was normal in patients with pancreatitis.